There’s potentially good news in the fight against the deadly scourge of malaria in Kenya. Clinical trials on a new anti-malarial drug that will hopefully tackle more drug-resistant forms of the mosquito-borne disease, are to be conducted in the country from December this year. The drug KAF156, has been developed by Novartis, a Swiss pharmaceutical […]